PatientSeek identifies a genetic signature that separates integrin a4b7 therapy responders from non-responders in inflammatory bowel disease.

C4X Discovery Holdings Limited

PatientSeek identifies a segregating genetic signature a4bRole of 7 integrin therapy and the non-responder population in inflammatory bowel disease

It promotes the correct method of patient selection – the right patient for the right drug

16 September 2024 – C4X Discovery Holdings Limited (“C4XD”), an immuno-oncology company, today announces the discovery of a genetic response signature that identifies groups of responders and non-responders among patients with peptic ulcer disease, inflammatory bowel disease (“IBD”), following treatment with the a4b7 integrin antibody vedolizumab.

Clive Dix, Executive Chairman of C4XD, said: “To date, no currently available biomarker has been robustly validated in predicting treatment response to advanced clinical practice for IBD, leaving many patients underserved. Using our PatientSeek platform we have now identified a genetic response signature that separates responders and non-responders to vedolizumab, a4b7 antibodies treatment of ulcerative colitis. This is a very exciting first for immuno-inflammation precision medicine as these data clearly demonstrate the potential of PatientSeek’s analysis in patient selection based on genetic data alone. We will use the predictive power of the data for use in future clinical trials for our small molecule a4b7 and we will take this precision approach to develop our growing pipeline, including our TNFa and PAD4 programs.”

Precision medicine aims to identify the right therapy that will be effective for the right patient at the right stage in the development of their disease. Originally contested in oncology, this approach is now gaining a lot of attention from the scientific and medical community in the immuno-inflammation space.

C4XD’s PatientSeek system uses a unique mathematical approach to analyze datasets containing patient genetic records as well as other information such as electronic health records. The resulting data can provide a statistically significant prediction of a ‘genetic response signature’. Genetic signatures, compared to clinical and omic markers, have the advantage of being time-invariant and independent of disease progression.

C4XD has accessed and analyzed a large data set that contains patients who have received vedolizumab and preliminary data have clearly shown that, for the first time, responders and non-responders can be separated according to a genetic signature based on genetic differences in non-coding. DNA regions. PatientSeek’s ability to identify genetic response signatures should lead to smaller, cheaper and more successful trials targeting the right patient at the right time with the right drug.

Address

Notes to Editors:

About C4X Discovery
C4X Discovery (C4XD) is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge technology to deliver the world’s most effective medicines. We have a valuable and differentiated approach to Drug Discovery through our enhanced molecular structure and patient stratification capabilities, providing small molecule drug candidates across multiple disease indications targeting immune inflammation. We are developing our internal portfolio that ranges from targeted early-stage opportunities to late-stage Drug Discovery programs and we have two co-commercial programs with Sanofi and AstraZeneca, and one clinical-stage candidate that has been acquired by Indivior.

For more information visit us at www.c4xdiscovery.com or follow us on twitter @C4XDiscovery.